Related Experiment Videos
Statins in primary biliary cirrhosis: are they safe?
Murad Abu Rajab1, Marshall M Kaplan
1Division of Gastroenterology, Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA.
Insights
Statins are safe for primary biliary cirrhosis (PBC) patients with high cholesterol. This study found no increase in liver enzymes and a significant decrease in cholesterol levels, indicating good tolerability and efficacy.
Area of Science:
- Hepatology
- Cardiology
- Pharmacology
Background:
- Primary biliary cirrhosis (PBC) patients often have elevated cholesterol levels.
- A subset of PBC patients (approx. 10%) exhibit dyslipidemia, potentially benefiting from lipid-lowering therapy.
- Concerns exist regarding statin use in patients with pre-existing liver conditions.
Purpose of the Study:
- To evaluate the safety and efficacy of statins in patients with primary biliary cirrhosis.
- To assess the impact of statins on liver enzymes and cholesterol levels in PBC patients.
Main Methods:
- Retrospective review of 603 PBC patients seen between 1996 and 2006.
- Analysis of data from 58 patients treated with statins and 5 with ezetimibe.
- Monitoring of alanine aminotransferase (ALT) levels at 3-month intervals during treatment.
Main Results:
- Statins were well-tolerated, with no reported muscle pain or weakness.
- No significant increase in ALT levels was observed; levels normalized or remained stable.
- Serum cholesterol levels decreased by approximately 30% (P < 0.01).
- Ezetimibe was also found to be well-tolerated.
Conclusions:
- Statins are a safe treatment option for primary biliary cirrhosis patients requiring cholesterol management.
- Lipid-lowering therapy with statins can effectively reduce cholesterol levels in PBC patients without adversely affecting liver function.
Background And Aim:
Although cholesterol levels are elevated in patients with primary biliary cirrhosis (PBC), most PBC patients are not at increased risk of dying from atherosclerotic heart disease. There is, however, a subgroup, approximately 10%, who have additional disorders of lipid metabolism. They might benefit from a cholesterol-lowering agent. However, there is concern about using statins in patients with pre-existing liver disease. We therefore reviewed our experience with statins in a large cohort of PBC patients who were seen at Tufts Medical Center during the past decade.
Methods:
From January 1, 1996, until June 30, 2006, 603 patients with PBC were seen by one of us (M.M.K.). Fifty-eight were on statins and five were on ezetimibe. The mean duration of usage was 41 months (range 3-125 months). Alanine aminotransferase (ALT) levels were measured at 3-month intervals.
Results:
Statins were well tolerated. No patient complained of muscle pain or weakness. There was no increase in ALT levels. ALT levels were slightly elevated at the time that statins were begun (41.7 +/- 25.1 U/l), and were normal at the last time these patients were seen (39.0 +/- 21.0 U/l) (P
Conclusion:
Statins are safe in PBC patients who might benefit from their use.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:26Atherosclerosis III: Management
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:20Cholecystitis